Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...

FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its ...

SAINT-PREX, Switzerland--(BUSINESS WIRE)--New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen ...

FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 ...

Please provide your email address to receive an email when new articles are posted on . Today the FDA announced the approval of the gonadotropin-releasing hormone receptor inhibitor degarelix for the ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for ...

Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...